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Clinical Case Triggering Attention to the Issue
A 29-year-old patient who was treated with buprenorphine for 2 years without recurrence attends
regular psychiatric controls that include screening for psychoactive substances. During one of the
visits, when he was accompanied by his parents, a test for psychoactive substances was positive
for opiates. The patient denied that he used illegal substances, and his parents claimed so as well.
During this period, the patient lived fairly in isolation, with themembers of his family. The only new
substance that he used was a new cartridge for e-cigarette. The cartridge was bought at the market in
another place, at a pretty low price. Since the father used the same cartridge, he offered to take the test
on PAS. The test was positive for opiates (father had never used psychoactive substances in his life).
This inspired us to do the following experiment: we poured the content of the cartridge into a glass
with water, and the test was again positive for opiates. In this case, neither the outcome of the test
of our patient and/or his father nor naive experiment (with the help of immunochromatographic
test for the simultaneous qualitative detection of drugs and their metabolites in the urine) or
experimental method that is highly dubious was important, but the questions (i.e., more questions)
that open after these clinical experiences.
The questions posed are: does any authority regularly control the composition of e-cigarettes, and
if so, which one, under what circumstances, and whether it is regulated by law?
Let us start from the known premise: electronic cigarettes (e-cigarettes) are battery-powered
devices that allow nicotine intake with chemicals that have different tastes by inhalation, and they
are substitutes for smoking ordinary cigarettes. It is known that there are over 250 different brands
of e-cigarettes currently on the market. It is estimated that the number of users of e-cigarettes in the
world is rapidly growing. In Europe, there are about 7million users of e-cigarettes. In France, there
are about 1.5million e-cigarette users, while, for example, in the UK, the number of e-cigarette users
has tripled since 2012 (from 700,000 to over 2million) (1).
The tobacco industry is investing a huge sum of money into the development of e-cigarettes, and
according to the researchers fromHSPH’s Center for Global Tobacco Control (CGTC), Department
of Social andBehavioral Sciences, it is very important to identify the subpopulation thatwill probably
use them more than others and determine the implications for public health. This research has
shown that millions of people – including many young people and smokers who want to stop
smoking – try e-cigarettes. This also points to the fact that the importance of determining the
potential harm (or benefit) is being underestimated (2). Each e-cigarette contains the following
components: batteries (mainly lithium ion) that can be automatic or manual; electronic atomizer
spray (responsible for controlling the operation of the device and the release of nicotine vapor during
inhalation); and tank in which the liquid for e-cigarette is poured (newer versions have atomizer
and tank in one unit, and such a device is called clearomizer). The first e-cigarette appeared on
the market in China in 2004, and since then, it is marketed as a healthier alternative to smoking.
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The biggest advantage of e-cigarette is, as stated in the advertise-
ments, that the smoker inhales only a controlled dose of nicotine
vapor that fulfills his need for smoking but does not inhale tar,
carbon monoxide, remnants of metal, mercury, and many other
harmful substances existing in each real cigarette. Also, according
to advertising, “it protects and preserves the health of passive
smokers, children also.”
Are e-Cigarettes Safe?
E-cigarettes contain nicotine and other potentially dangerous sub-
stances. Except for nicotine, which is known to be highly addic-
tive substance, other found chemicals, such as formaldehyde and
acetaldehyde, are toxic and carcinogenic. In inhaled air from e-
cigarette, nanoparticles ofmetal were found. Health consequences
after consuming e-cigarettes are not known (3).
Users of e-cigarettes use cartridges with different concentra-
tions of nicotine (and other substances), and so, potentially, they
may be exposed to toxic concentrations of the same. The concen-
tration of nicotine was ranked in the range from 0 to 34mg/mL,
but recent studies show a discrepancy between the indicated con-
centrations of nicotine on the bottle with filling and measured
concentrations (4). E-cigarettes produce aerosol, which contains
nicotine, and since that aerosol is heated (temperature depends
on the design of the e-cigarette), it affects the aerosolization of
the nicotine and its activity (5). Nicotine affects the peripheral
nervous system and the central nervous system and represents the
primary addictive ingredient with non-nicotine substances, such
as anabasine, nornicotine, and acetaldehyde, which also affect the
addiction to tobacco. FDA analysis showed the presence of anaba-
sine in several types of e-cigarettes (6). In 20 different models
of the e-cigarette, the presence of alkaloids similar to nicotine,
such as nornicotine and anabasine, was found (7). Given that
e-cigarettes are so different in design and content of nicotine,
it makes it difficult to compare and assess the pharmacologi-
cal properties of content, and therefore, the addictive and toxic
potential.
Do Regulatory Authorities Conduct
Periodical Audit of Composition of
e-Cigarette Cartridges?
Until recently, in most European countries, e-cigarettes were not
treated either as a tobacco product or as a medical agent. This
means that the only law that controls them is the national Con-
sumer Protection Act that deals exclusively with the technical
characteristics of products. Many contemporary laws on tobacco
in the EU did not mention e-cigarettes as a tobacco product,
and so they were not subject to stricter regulations. European
Parliament in February 2014 approved that the products that have
nicotine concentrations up to 20mg/mL can be considered as
tobacco products and that those with a higher concentration or
used for therapeutic purposes can be considered amedicinal agent
(8). However, this decision is left to the member countries them-
selves. This Directive insists on the health warning, mandatory
information regarding the ingredients, and the side effects that
package must contain.
Cartridges that can be refilled are allowed if their volume does
not exceed 2mL (or if at least three member countries estimate
that they are potentially dangerous to health, they may be pro-
hibited by the European Commission). In the UK, although there
were indications that the e-cigarette will be declared a medical
agent that is used for smokers who want to stop this habit, this has
not happened still. E-cigarettes are treated as a “consumer prod-
uct.” Restrictions relating to the marketing of e-cigarettes have
not yet been introduced (9). The US Department of Health and
Human Services (FDA) has proposed in April 2014 a set of regu-
latory rules relating to the control of e-cigarettes. Just e-cigarettes
that are used for therapeutic purposes are currently regulated by
the FDA (Center for Drug Evaluation and Research – CDER).
According to the FDA reports, voluntary reports of adverse
effects of e-cigarettes, which include reports of consumers, med-
ical professionals, and public, are regularly arriving. Adverse
events that required even hospitalization described in these
reports are pneumonia, congestive heart failure, disorientation,
epileptic seizures, hypotension, and other health problems (10).
E-cigarettes are manufactured in China and quality control is
variable (11). Users canmodifymany products and even use other
substances (e.g., marijuana) via e-cigarette.
State-of-the-Art Clinical Research
on e-Cigarettes
A relatively small number of clinical studies investigate the effect
of e-cigarettes on health of people. Some of them show that e-
cigarettes can “deliver” a similar amount of nicotine as traditional
cigarettes (12, 13). Others show that the utilization of nicotine
from e-cigarettes depends on the user experience and habits in use
(7). Bahl et al. tested for cytotoxicity in 41 e-cigarettes produced
by four different companies, using three types of cells: lung fibrob-
lasts, embryonic stem cells (both of human origin), and neural
stem cells of a mouse. Cytotoxicity varied among the products
from highly toxic to non-toxic. Nicotine did not cause toxicity
but other components did. It is important to point out that what
was non-toxic to lung fibroblasts was extremely toxic to both
types of stem cells (14). The research done by Schober and his
associates measuring pollution in the room where three people
smoked e-cigarette over a period of 2 h is interesting. The increase
in the concentration of nicotine, 1,2-propanediol, aluminum,
glycerin, and seven polycyclic aromatic hydrocarbons were clas-
sified as probably carcinogenic by the International Agency for
research on Cancer (15). Propylene glycol and glycerin are the
main ingredients of cigarettes. Exposure to propylene glycol can
lead to irritation of the eyes and lungs, and repeated inhalation
leads to effects on the CNS, behavior, and results in damage
to the spleen (16). The conclusion is that a very small number
of studies investigate the direct health effects, but some suggest
that aerosols from e-cigarettes have biological effect. Long-term
biological effects are still unknown, given that e-cigarettes are a
relatively new invention.
Let us go back to the beginning of the story: it is obvious
that we do not know the composition of e-cigarettes, even when
we think it is known and controlled by the competent regu-
latory authorities. The health effects of “known” components
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of aerosols emitted by e-cigarettes are unknown. There are not
enough research/clinical studies on the topic of the impact/risk
to human health.
Increasingly, these electronic devices are used for the enjoyment
of other PAS. Marijuana is mostly used in liquid form or in the
form of wax. It is perfect for users since there is no characteristic
odor that occurs when smoking marijuana. This way, unimpeded
by police or similar services, illegal drugs can be used or smuggled.
This is certainly a new reason to think about.
Concern regarding the quality control and health outcomes
is justified. It will be necessary to evolve legal framework to
regulate the production and circulation of e-cigarettes and deter-
mine their actual effect on health. Anyway, one of the first
steps is regulation that will allow finally that e-cigarettes come
under the scrutiny of the professional public for its initial
market access stage. Thus, in the upcoming years, full clin-
ical potential as well as room to avoid key adverse events
would become better known to the consumers and addictologists
as well.
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